naproxen etemesil

Naproxen etemesil is a small molecule, non-acidic, lipophilic prodrug of the nonsteroidal anti-inflammatory drug (NSAID) naproxen. It is hydrolyzed in the body to release active naproxen after absorption. The primary mechanism of action is through inhibition of cyclooxygenase enzymes (COX-1 and COX-2), leading to reduced prostaglandin synthesis and thus decreased inflammation and pain. Naproxen etemesil was developed for improved gastrointestinal tolerability compared to standard naproxen formulations. It has been investigated primarily for the treatment of osteoarthritis and other inflammatory conditions, reaching up to phase II clinical trials[2][3][5]. The compound was originally developed by Medinox and later licensed to Logical Therapeutics[5].

Other names

naproxen etemesil385800-16-8